is on track to meet its contractual obligation to the Government ahead of the agreed delivery schedule by supplying both filled and finished as well as finished Sinovac Covid-19 vaccine.
In a statement Wednesday, the pharmaceutical company said it would be able to supply a total of 8.6 million doses by end June 2021.
“Pharmaniaga’s wholly-owned subsidiary Pharmaniaga LifeScience Sdn Bhd (PLS) is also ready to ramp up production from 2 million to 4 doses a month in order to help the Government expedite the vaccination programme and achieve herd immunity,” it said.
Group managing director Datuk Zulkarnain Md Eusope said up to May 23, PLS’s high-tech plant had completed fill and finish manufacturing a total of 1.88 million doses of Sinovac Covid-19 doses.
KUALA LUMPUR: Authorities should source vaccines other than Pfizer, Sinovac and AstraZeneca to speed up the National Covid-19 Immunisation Programme, says Tan Sri Lee Lam Thye.
news
Private Company Says MOH Has Approved Its Phase 3 Clinical Trial Of COVID-19 Vaccine
The company, which deals in tourism and property, stated that this will help Malaysia attract huge investment as well as create job opportunities in the pharmaceutical sector.
By Sadho Ram â 28 Apr 2021, 06:07 PM
Subscribe to our Telegram channel for our latest stories and breaking news.
A property developer has obtained the Ministry of Health s approval for its Phase 3 clinical trial study of inactivated COVID-19 trial vaccines in Malaysia, as per its announcement on Bursa Malaysia
With the approval, the property developer Yong Tai Berhad â under its healthcare subsidiary YTB Healthcare Sdn Bhd (YTBH) â has become the first private company to initiate and sponsor the Phase 3 clinical trial of the COVID-19 vaccines in Malaysia.
KUALA LUMPUR (April 26): Property developer Yong Tai Bhd said its healthcare subsidiary has obtained approval from the Ministry of Health s Medical Review & Ethics Committee (MREC) for its Phase III clinical trial study of inactivated Covid-19 trial vaccines in Malaysia. The board wishes to announce that MREC had vide its letter dated April 23, approved the said Phase III Clinical Trial study to be carried out in Malaysia involving 3,000 subjects, the group said in a bourse filing today.
The health ministry has not made a statement on this matter so far.
Yong Tai said its unit, YTB Healthcare Sdn Bhds (YTBH), has formalised the Phase III clinical trial with its partner, Shenzhen Kangtai Biological Products Co Ltd (SZKT), since December last year. SZKT is a vaccine manufacturer in China.
Khairy dismisses talk of Malaysian federal government blocking states COVID-19 vaccine procurement channelnewsasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from channelnewsasia.com Daily Mail and Mail on Sunday newspapers.